Moderna says Covid-19 vaccine boosted antibodies in early-stage trial
Published
Worldwide hope for a Covid-19 vaccine got a boost Monday after Cambridge biotech Moderna Inc. reported that its candidate showed positive effects in an early-stage study. In a Phase 1 test, participants that received doses of Moderna’s (Nasdaq: MRNA) potential Covid-19 vaccine developed the same or greater amounts of virus-fighting antibodies than people who have recovered from the disease, according to a press release. The effects were seen with both the low and high doses of the vaccine,…
Full Article